Oral pill trial delivers rare complete responses in advanced pancreatic cancer
Barcelona — November 20, 2026 · 11:46 a.m. CST (17:46 UTC).
A targeted daily pill called daraxonrasib helped wipe out detectable tumors on CT scans in roughly one in 12 patients with advanced pancreatic cancer during a closely watched clinical trial, researchers reported this week—sparking optimism among oncologists alongside firm warnings not to call the treatment a cure.
Updated Phase 1/2 results from the RMC-GI-102 trial, presented at the EORTC-NCI-AACR (ENA) Symposium in Barcelona and reported Friday by BBC News, The Independent, and The Telegraph, tested daraxonrasib alongside standard chemotherapy in 61 previously untreated patients whose pancreatic ductal adenocarcinoma had already spread.
In 8.2% of those patients—about one in 12—tumors became completely undetectable on follow-up scans, according to data released by developer Revolution Medicines via GlobeNewswire. Overall, 60.7% of trial participants saw significant tumor shrinkage, while disease growth stopped in 90.2% of patients.
How the drug targets a mutation long considered undruggable
Pancreatic cancer has long ranked among the most lethal solid tumors in medicine, largely because it is frequently diagnosed after spreading and responds poorly to standard chemotherapy alone. More than 90% of pancreatic tumors carry mutations in the KRAS gene, which acts like a stuck accelerator pedal driving nonstop cell growth.
Daraxonrasib—marketed under the brand name Rasonque and previously known as RMC-6236—is an oral pan-RAS(ON) inhibitor designed to lock onto and block active mutated RAS proteins. In the Barcelona presentation, Memorial Sloan Kettering Cancer Center medical oncologist Dr. Wungki Park paired the once-daily pill with gemcitabine and nab-paclitaxel as a first-line regimen.
Beyond tumor shrinkage, the trial posted a median progression-free survival of 12.8 months and an estimated 12-month overall survival rate of 76.6% over a median follow-up of 18.3 months, according to the study release—well above typical one-year survival rates of roughly 40% to 45% seen historically with standard chemotherapy alone.